The U.S. Food and Drug Administration on Friday approved GSK’s respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the shot’s accessibility to younger patients…
Source : United Press International
The U.S. Food and Drug Administration on Friday approved GSK’s respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the shot’s accessibility to younger patients…
Source : United Press International
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More